No Data
No Data
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Last Week's 5.0% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
hubei jumpcan pharmaceutical (600566.SH): has repurchased a total of 0.1805 million shares.
Gelonghui September 30th | Hubei Jumpcan Pharmaceutical (600566.SH) announced that as of September 30, 2024, the company has repurchased a total of 180,500 shares through centralized bidding trading, accounting for 0.02% of the total share capital of the company. The highest purchase price is 29.00 yuan/share, the lowest price is 27.29 yuan/share, and the total amount paid is RMB 5,004,978 (excluding transaction costs).
An Intrinsic Calculation For Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) Suggests It's 46% Undervalued
Zhongtai Securities: Short-term performance pressure in the traditional Chinese medicine sector, with main focus on improving quality and efficiency.
Against the backdrop of high base numbers in H1 2023, the traditional chinese medicine sector's performance is under short-term pressure. With the fading of the base effect and the arrival of the peak season in autumn and winter, the sector's performance is expected to gradually improve.
Hubei Jumpcan Pharmaceutical (600566.SH): the company's products are not included in the Anhui Provincial procurement scope.
On September 12, Hubei Jumpcan Pharmaceutical (600566.SH) stated on the interactive platform that the company's products have not been included in the Anhui Province centralized procurement scope. The company closely monitors the changes and progress of the centralized procurement policy and actively prepares for it.
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
No Data
No Data